Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25428252 | 0.85 | UCHL1 (0.43) | UCHL1FFAR1 | |
| SCHEMBL30200828 | 0.85 | UCHL1 (0.42) | UCHL1FFAR1 | |
| SCHEMBL18125399 | 0.84 | UCHL1 (0.45) | UCHL1FFAR1 | |
| SCHEMBL1358786 | 0.82 | UCHL1 (0.41) | UCHL1FFAR1 | |
| SCHEMBL21266884 | 0.80 | UCHL1 (0.43) | UCHL1FFAR1 | |
| SCHEMBL30200601 | 0.80 | FFAR1 (0.43) | UCHL1FFAR1 | |
| SCHEMBL30508697 | 0.79 | UCHL1 (0.40) | UCHL1FFAR1 | |
| SCHEMBL21266730 | 0.78 | UCHL1 (0.38) | UCHL1FFAR1 | |
| SCHEMBL25428501 | 0.78 | UCHL1 (0.39) | UCHL1FFAR1 | |
| SCHEMBL24896720 | 0.78 | UCHL1 (0.44) | UCHL1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| EP-4401729-A1 | BCL-XL DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| WO-2023044046-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | XIAP, BCL2L1, BCL2L10 | UCHL1 35/4885FFAR1 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.